12/22
04:11 pm
nbix
Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy [Yahoo! Finance]
Low
Report
Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy [Yahoo! Finance]
12/22
04:05 pm
nbix
Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy
Low
Report
Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy
12/17
08:05 am
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at HC Wainwright from $168.00 to $198.00. They now have a "buy" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at HC Wainwright from $168.00 to $198.00. They now have a "buy" rating on the stock.
12/16
07:13 pm
nbix
Neurocrine Biosciences, Inc. (NBIX) Discusses Progress and Strategy in Neurology and Obesity R&D Programs Transcript [Seeking Alpha]
Medium
Report
Neurocrine Biosciences, Inc. (NBIX) Discusses Progress and Strategy in Neurology and Obesity R&D Programs Transcript [Seeking Alpha]
12/16
04:38 pm
nbix
Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology [Yahoo! Finance]
Medium
Report
Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology [Yahoo! Finance]
12/16
04:01 pm
nbix
Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology
Medium
Report
Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology
12/12
09:48 am
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Mizuho from $146.00 to $175.00. They now have a "neutral" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Mizuho from $146.00 to $175.00. They now have a "neutral" rating on the stock.
12/11
08:44 am
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Stifel Nicolaus from $183.00 to $188.00. They now have a "buy" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Stifel Nicolaus from $183.00 to $188.00. They now have a "buy" rating on the stock.
12/9
04:25 pm
nbix
Neurocrine Biosciences to Host R&D Day on December 16 [Yahoo! Finance]
Low
Report
Neurocrine Biosciences to Host R&D Day on December 16 [Yahoo! Finance]
12/9
04:01 pm
nbix
Neurocrine Biosciences to Host R&D Day on December 16
Low
Report
Neurocrine Biosciences to Host R&D Day on December 16
12/8
09:56 am
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Royal Bank Of Canada from $160.00 to $180.00. They now have an "outperform" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Royal Bank Of Canada from $160.00 to $180.00. They now have an "outperform" rating on the stock.
12/5
12:19 pm
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at TD Cowen from $175.00 to $200.00. They now have a "buy" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at TD Cowen from $175.00 to $200.00. They now have a "buy" rating on the stock.
11/28
04:33 am
nbix
Neurocrine Biosciences (NBIX): Revisiting Valuation Following Decade-Long VMAT2 Review Publication [Yahoo! Finance]
Low
Report
Neurocrine Biosciences (NBIX): Revisiting Valuation Following Decade-Long VMAT2 Review Publication [Yahoo! Finance]
11/20
08:30 am
nbix
Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules
Low
Report
Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules
11/18
04:57 pm
nbix
Neurona Therapeutics Appoints Dr. Eduardo Dunayevich as Chief Medical Officer [Yahoo! Finance]
Low
Report
Neurona Therapeutics Appoints Dr. Eduardo Dunayevich as Chief Medical Officer [Yahoo! Finance]
11/12
07:10 pm
nbix
Assessing Neurocrine Biosciences After Stock Rises 7.8% and Partnership Expansion News [Yahoo! Finance]
Low
Report
Assessing Neurocrine Biosciences After Stock Rises 7.8% and Partnership Expansion News [Yahoo! Finance]
11/11
04:01 pm
nbix
Neurocrine Biosciences to Present at Upcoming Investor Conferences
Low
Report
Neurocrine Biosciences to Present at Upcoming Investor Conferences
11/11
08:09 am
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at Morgan Stanley from $178.00 to $173.00. They now have an "overweight" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at Morgan Stanley from $178.00 to $173.00. They now have an "overweight" rating on the stock.
11/10
07:08 pm
nbix
Neurocrine chalks up a depression drug failure [Yahoo! Finance]
Low
Report
Neurocrine chalks up a depression drug failure [Yahoo! Finance]
11/10
04:09 pm
nbix
Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder [Yahoo! Finance]
Medium
Report
Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder [Yahoo! Finance]
11/10
04:05 pm
nbix
Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder
Low
Report
Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder
11/3
10:42 am
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at JPMorgan Chase & Co. from $171.00 to $179.00. They now have an "overweight" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at JPMorgan Chase & Co. from $171.00 to $179.00. They now have an "overweight" rating on the stock.
10/30
09:04 am
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its "buy" rating reaffirmed by analysts at Truist Financial Corporation. They now have a $172.00 price target on the stock, up previously from $165.00.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its "buy" rating reaffirmed by analysts at Truist Financial Corporation. They now have a $172.00 price target on the stock, up previously from $165.00.
10/29
04:48 pm
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Canaccord Genuity Group Inc. from $160.00 to $164.00. They now have a "buy" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Canaccord Genuity Group Inc. from $160.00 to $164.00. They now have a "buy" rating on the stock.
10/29
02:51 pm
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Citigroup Inc. from $175.00 to $203.00. They now have a "buy" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Citigroup Inc. from $175.00 to $203.00. They now have a "buy" rating on the stock.